Drug Profile


Alternative Names: Exanta™; H 376; H 376/95; H 37695

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Deep vein thrombosis; Thromboembolism
  • Discontinued Postmyocardial infarction; Stroke

Most Recent Events

  • 17 Feb 2006 Clinical data from a media release have been added to the adverse events section
  • 14 Feb 2006 Discontinued - Phase-II for Postmyocardial infarction in Sweden (PO)
  • 14 Feb 2006 Discontinued - Phase-II for Postmyocardial infarction in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top